0001209191-22-017669.txt : 20220309 0001209191-22-017669.hdr.sgml : 20220309 20220309181433 ACCESSION NUMBER: 0001209191-22-017669 CONFORMED SUBMISSION TYPE: 4/A PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20211004 FILED AS OF DATE: 20220309 DATE AS OF CHANGE: 20220309 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Ong Tuyen CENTRAL INDEX KEY: 0001673178 FILING VALUES: FORM TYPE: 4/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-39438 FILM NUMBER: 22726706 MAIL ADDRESS: STREET 1: C/O PTC THERAPEUTICS, INC. STREET 2: 100 CORPORATE COURT CITY: SOUTH PLAINFIELD STATE: NJ ZIP: 07080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Gemini Therapeutics, Inc. /DE CENTRAL INDEX KEY: 0001816736 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 851613057 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 300 ONE KENDALL SQUARE, 3RD FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: (617) 401-4400 MAIL ADDRESS: STREET 1: 300 ONE KENDALL SQUARE, 3RD FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER COMPANY: FORMER CONFORMED NAME: FS Development Corp. DATE OF NAME CHANGE: 20200702 4/A 1 doc4a.xml FORM 4/A SUBMISSION X0306 4/A 2021-10-04 2021-10-06 0 0001816736 Gemini Therapeutics, Inc. /DE GMTX 0001673178 Ong Tuyen C/O GEMINI THERAPEUTICS, INC. NOT APPLICABLE DE 1 0 0 0 Stock Option (Right to Buy) 3.80 2021-10-04 4 A 0 15528 0.00 A 2031-10-03 Common Stock 15528 15528 D This option shall vest and become exercisable on the earlier of (a) the one (1)-year anniversary of the Grant Date and (b) the Company's next annual meeting of stockholders, in each case, so long as the Optionee continues to have a Service Relationship with the Company on such date. This Form 4/A amends and restates the original Form 4 filed on October 6, 2021 to correct the number of stock options granted to the Reporting Person. /s/ Brian Piekos, attorney-in-fact 2022-03-09 EX-24 2 attachment1.htm EX-24 DOCUMENT

Exhibit 24
                               POWER OF ATTORNEY

       Know all by these presents, that the undersigned hereby constitutes and
appoints each of Brian Piekos and Nina Thayer signing singly, the undersigned's
true and lawful attorney-in-fact to:

      (1)    execute for and on behalf of the undersigned, in the undersigned's
             capacity as an officer and/or director of Gemini Therapeutics, Inc.
             (the "Company"), (i) Form ID, including any attached documents, to
             effect the assignment of codes to the undersigned to be used in the
             transmission of information to the United States Securities and
             Exchange Commission using the EDGAR System, (ii) Forms 3, 4 and 5,
             (iii) Schedule 13D, (iv) Schedule 13G and (v) amendments of each
             thereof, in accordance with Section 16(a) of the Securities
             Exchange Act of 1934, as amended, and the rules thereunder;


      (2)    do and perform any and all acts for and on behalf of the
             undersigned which may be necessary or desirable to complete and
             execute any such Form 3, 4 or 5, Schedule 13D. Schedule 13G or any
             amendments thereto and timely file such form with the United States
             Securities and Exchange Commission and any stock exchange or
             similar authority; and


      (3)    take any other action of any type whatsoever in connection with
             the foregoing which, in the opinion of such attorney-in-fact, may
             be of benefit to, in the best interest of, or legally required by,
             the undersigned, it being understood that the documents executed by
             such attorney-in-fact on behalf of the undersigned pursuant to this
             Power of Attorney shall be in such form and shall contain such
             terms and conditions as such attorney-in-fact may approve in such
             attorney-in-fact's discretion.




      The undersigned hereby grants to each such attorney-in-fact full power
and authority to do and perform any and every act and thing whatsoever
requisite, necessary, or proper to be done in the exercise of any of the rights
and powers herein granted, as fully to all intents and purposes as the
undersigned might or could do if personally present, with full power of
substitution or revocation, hereby ratifying and confirming all that such
attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall
lawfully do or cause to be done by virtue of this Power of Attorney and the
rights and powers herein granted. The undersigned acknowledges that the
foregoing attorneys-in-fact, in serving in such capacity at the request of the
undersigned, are not assuming, nor is the Company assuming, any of the
undersigned's responsibilities to comply with Section 16 or Regulation 13D-G of
the Securities Exchange Act of 1934, as amended. The undersigned hereby agrees
to indemnify the attorney-in-fact and the Company from and against any demand,
damage, loss, cost or expense arising from any false or misleading information
provided by the undersigned to the attorney-in-fact.



      This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4 and 5 with respect to the
undersigned's holdings of and transactions in securities issued by the Company,
unless earlier revoked by the undersigned in a signed writing delivered to the
foregoing attorneys-in- fact. This Power of Attorney may be filed with the
United States Securities and Exchange Commission as a confirming statement of
the authority granted herein. This Power of Attorney supersedes any prior power
of attorney in connection with the undersigned's capacity as an officer and/or
director of the Company. This Power of Attorney shall expire as to any
individual attorney-in-fact if such attorney-in-fact ceases to be an executive
officer of the Company.

       IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to
be executed as of this 9th day of March, 2022.


/s/ Tuyen Ong
-------------------
Name: Tuyen Ong